Peripheral artery disease affects up to 12% of the U.S. population, but is often under-diagnosed and inadequately treated. ... Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease.
Despite poor awareness and a lack of training on handling peripheral artery disease, internists can and should be able to recognize the symptoms and manage 95% of such cases. ... A ratio of 0.90 or less indicates peripheral artery disease. Its
Peripheral artery disease (PAD) has a bigger public health impact than many better known coronary vascular diseases, but awareness of symptoms and interventions lag behind, an expert said. ... The technologies for screening, diagnosing and caring for
News from Digestive Disease Week: PPIs and CAT. CHICAGO--Is there a link between acid-reducing meds and hip fractures? ... These patients were likely to be on aspirin-anticoagulant-antiplatelet therapy for a history of ischemic heart disease, hypertension
death, and need for revascularization in patients with a previous heart attack or peripheral artery disease. ... Vorapaxar (Zontivity) to reduce the risk of heart attack, stroke, cardiovascular death, and need for revascularization in patients with a
their rehabilitation on recovery, but the prevention of a subsequent stroke, as well as CAD and peripheral artery disease, is also an important task,” the authors wrote.
Tobacco remains the single largest preventable cause of death and disease in the United States. ... Congestive heart failure. --Stroke. --Atherosclerosis. --Abdominal aortic aneurysm. --Peripheral artery disease.
Peripheral artery disease is a common, and significant, problem estimated to affect up to 12% of people in the United States. ... Peripheral artery disease (PAD) is a common, and significant, problem estimated to affect up to 12% of people in the United
A reader responds about physical exams for PAD. The author of the fine article on peripheral artery disease (PAD) [“An easy screen for an overlooked disease,” ACP Internist, April 2011] neglected
It was approved based on data from the ADVANCE trial. The Zilver PTX stent, the first drug-eluting stent indicated to re-open the femoropopliteal artery when narrowed or blocked as ... a result of peripheral artery disease.